Australia Infant Phototherapy Device Market Size and Forecast 2025–2033

Australia Infant Phototherapy Device Market Overview

The Australia Infant Phototherapy Device Market is estimated to reach US$ 2.47 billion by 2033, rising from US$ 1.88 billion in 2024, and expanding at a CAGR of 3.1% during 2025–2033. Market growth is primarily supported by the rising prevalence of neonatal jaundice, increasing awareness of early infant healthcare, and continued advancements in safe, non-invasive phototherapy technologies across Australian hospitals and neonatal intensive care units (NICUs).

Download Free Sample Report

Infant phototherapy devices are specialized medical systems designed to treat neonatal jaundice, a common condition in newborns caused by elevated bilirubin levels in the blood. These devices emit controlled blue light wavelengths (460–490 nm) that help convert bilirubin into water-soluble forms, enabling safe excretion from the infant’s body. The therapy is widely recognized as effective, painless, and non-invasive when administered promptly.

Australia’s well-established healthcare infrastructure, combined with standardized newborn screening protocols, has made phototherapy a routine component of neonatal care. Hospitals increasingly favor LED-based phototherapy systems due to their superior energy efficiency, lower heat emission, and enhanced safety compared with traditional fluorescent lamps. Government initiatives focused on improving maternal and infant outcomes further reinforce long-term market demand.

Market Outlook: Australia Infant Phototherapy Device Industry

Infant phototherapy equipment is deeply integrated into Australia’s neonatal services, particularly in maternity wards, pediatric hospitals, and NICUs. Early screening for jaundice is standard practice, ensuring timely diagnosis and treatment. As parental awareness of newborn health continues to grow, demand for reliable and technologically advanced phototherapy solutions is steadily increasing.

Technological innovation remains central to market expansion. LED-based systems, fiber-optic phototherapy blankets, and smart intensity-controlled devices are improving treatment efficiency while enhancing infant comfort. Additionally, Australia’s emphasis on equitable healthcare access is encouraging the deployment of mobile phototherapy units in rural and remote regions.

Key Growth Drivers in the Australia Infant Phototherapy Device Market

Rising Prevalence of Neonatal Jaundice

Neonatal jaundice remains one of the most frequently diagnosed conditions among newborns in Australia, often linked to premature birth or underdeveloped liver function. Early detection is prioritized to prevent complications such as kernicterus. With nearly 289,100 births recorded in Australia in 2023, the volume of newborn screening directly supports sustained demand for phototherapy equipment. Increased awareness among parents and caregivers further accelerates adoption across healthcare facilities.

Technological Advancements in Phototherapy Devices

The transition from fluorescent-based systems to LED phototherapy devices represents a major technological shift in the market. LED units offer longer lifespans, lower operational costs, and reduced heat output, making them safer for prolonged use. Innovations such as adjustable irradiance, compact designs, and fiber-optic blankets are enhancing clinical outcomes and expanding usage in both hospital and outreach settings.

Government Support and Strong Healthcare Infrastructure

Australia’s public healthcare system plays a critical role in facilitating access to neonatal treatments. Government funding for hospitals, rural outreach programs, and staff training ensures widespread adoption of phototherapy devices. Inclusion of neonatal equipment in procurement policies and maternal health initiatives supports consistent demand nationwide.

Challenges Facing the Australia Infant Phototherapy Device Market

High Equipment Costs and Budget Constraints

Advanced LED-based phototherapy systems involve higher upfront costs, which can be challenging for smaller hospitals and clinics, particularly in rural areas. Budget limitations may delay upgrades or result in continued use of older fluorescent systems, leading to uneven technology penetration across regions.

Limited Access in Remote and Indigenous Communities

Geographic disparities remain a concern in Australia’s vast landscape. Remote and Indigenous populations may face delayed access to neonatal phototherapy services, often requiring transportation to urban hospitals. Addressing this challenge will require greater investment in mobile phototherapy solutions and expanded training for healthcare professionals in underserved regions.

Market Segmentation Analysis

By Light Source

Fluorescent Lamps

Once the standard in neonatal wards, fluorescent phototherapy devices are gradually being phased out. While more affordable initially, they generate more heat and require frequent bulb replacement. Their usage persists mainly in cost-sensitive or remote facilities, but long-term growth is limited.

Light Emitting Diodes (LEDs)

LED-based phototherapy devices dominate the market due to superior safety, efficiency, and durability. Hospitals across Australia increasingly prioritize LEDs for both fixed and mobile installations, making this segment the fastest-growing.

By Configuration

Mobile Phototherapy Devices

Mobile units offer flexibility and are particularly valuable in space-constrained NICUs, rural clinics, and outreach programs. Their portability supports decentralized neonatal care and, in some cases, supervised home-based treatment, driving steady demand.

Fixed Phototherapy Devices

Fixed systems remain essential in large hospitals and NICUs, providing high-intensity, continuous treatment. Their reliability and stability make them ideal for high-patient-volume environments, despite limited mobility.

By End User

Hospitals

Hospitals represent the largest end-user segment, driven by high birth volumes and access to NICUs. Public and private hospitals continue to invest in advanced phototherapy systems, supported by government subsidies and structured procurement programs.

Neonatal Clinics

Specialized neonatal clinics and maternity centers increasingly adopt compact and mobile phototherapy devices, especially in regional and suburban areas.

Regional Market Insights

Victoria

Victoria holds a significant share of the market, supported by advanced healthcare infrastructure and a high concentration of urban hospitals in Melbourne. Continuous investment in neonatal technology and strong public health programs sustain demand.

Queensland

Queensland’s vast geography drives demand for both fixed and mobile phototherapy systems. While metropolitan areas host advanced facilities, rural regions increasingly rely on portable LED units to improve access to neonatal care.

Tasmania

Despite a smaller population, Tasmania maintains high healthcare standards. Hospitals in Hobart and Launceston are well equipped, while mobile phototherapy devices support neonatal care in regional communities.

Western Australia

Western Australia’s expansive and remote terrain presents logistical challenges. Urban hospitals are well resourced, and increasing efforts are underway to deploy compact phototherapy devices to remote Aboriginal communities, supporting equitable healthcare access.

Competitive Landscape and Key Players

The Australian infant phototherapy device market features a mix of global and regional manufacturers focused on innovation, safety, and clinical efficiency. Key players include:

Koninklijke Philips N.V.

General Electric Company

Drägerwerk AG & Co. KGaA

Natus Medical Incorporated

Ningbo David Medical Device Co., Ltd

Inspiration Healthcare Group Plc

Ibis Medical Equipment and Systems Pvt Ltd

Weyer GmbH

Each company is evaluated across five viewpoints: Overview, Key Personnel, Recent Developments, SWOT Analysis, and Revenue Performance, highlighting competitive strategies and innovation trends shaping the market.

Market Segmentation Summary

By Light Source

Fluorescent Lamps

Light Emitting Diodes

Quartz Halogen Lamps

Gas Discharge Tubes

By Configuration

Mobile Devices

Fixed Devices

By End User

Hospitals

Neonatal Clinics

By Region

New South Wales

Victoria

Queensland

Western Australia

South Australia

Australian Capital Territory

Tasmania

Northern Territory

Final Thoughts

The Australia Infant Phototherapy Device Market is positioned for stable and sustainable growth through 2033, supported by strong healthcare infrastructure, standardized neonatal screening, and continuous technological innovation. While challenges such as equipment costs and geographic disparities remain, increasing adoption of LED-based and mobile phototherapy solutions is helping bridge gaps in neonatal care access.

With government backing, rising awareness of early infant health, and ongoing investment by leading medical device manufacturers, phototherapy will remain a cornerstone of neonatal treatment in Australia. The market’s evolution reflects a broader commitment to improving newborn outcomes through safe, effective, and accessible medical technologies—ensuring healthier starts for future generations.